


## (S,R,S)-AHPC-PEG3-NH2

|                           |   |       |          |
|---------------------------|---|-------|----------|
| <b>Cat. No.:</b>          | HY-103602A  |       |          |
| <b>CAS No.:</b>           | 2010159-56-3  |       |          |
| <b>Molecular Formula:</b> | C <sub>30</sub> H <sub>45</sub> N <sub>5</sub> O <sub>7</sub> S |       |          |
| <b>Molecular Weight:</b>  | 619.77  |       |          |
| <b>Target:</b>            | E3 Ligase Ligand-Linker Conjugates                              |       |          |
| <b>Pathway:</b>           | PROTAC  |       |          |
| <b>Storage:</b>           | Powder  | -20°C | 3 years  |
|                           |   | 4°C   | 2 years  |
|                           | In solvent  | -80°C | 6 months |
|                           |   | -20°C | 1 month  |



### BIOLOGICAL ACTIVITY

|                                     |   |
|-------------------------------------|---|
| <b>Description</b>                  | (S,R,S)-AHPC-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology. |
| <b>IC<sub>50</sub> &amp; Target</b> | VHL   |

### REFERENCES

[1]. Chan KH, et al. Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds. J Med Chem. 2018 Jan 25;61(2):504-513.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA